



FOR IMMEDIATE RELEASE

Media Contact: Kathryn Kempf  
973-746-8183

## **MIGRANAL WEB SITE LAUNCHES**

### **COMPASS HEALTHCARE COMMUNICATIONS CREATES SITE FOR VALEANT PHARMACEUTICALS**

Princeton, N.J., June 11, 2007 – A new Web site for Migranal® (dihydroergotomine mesylate), a nasal spray migraine medication, has been launched to meet the needs of medical professionals, Compass Healthcare Communications announced.

Migranal’s new Web site has specific features for neurologists and other general practice physicians who treat migraine patients. The site was designed, implemented and will be measured by Compass Healthcare Communications, a leading independent, full-service, online marketing agency exclusively serving the healthcare industry.

The goal for the site is to continue to increase awareness among the professional community of a commonly overlooked, but substantial roadblock to successful migraine treatment: patients often delay taking their medication. Migranal is a product of Valeant Pharmaceuticals International.

“Physicians know that successful migraine relief depends on using the right medications at the right time,” said Peter H. Nalen, president and CEO of Compass Healthcare Communications. “Migranal.com presents physicians with information about treatment options even after a migraine has started.”

#### **About Valeant Pharmaceuticals**

Valeant Pharmaceuticals International [NYSE: VRX] is a global specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at [www.valeant.com](http://www.valeant.com).

###